CA-CONVIVA
9.9.2021 04:02:12 CEST | Business Wire | Press release
Conviva, the intelligence cloud for streaming media, released its State of Streaming: Europe report for Q2 2021 today, revealing streaming growth in Europe held onto pandemic gains, growing 19% year over year and outpacing global streaming growth (13%) for the same time period. Western Europe led Europe’s streaming growth with 32% year over year gains, followed by northern Europe at 23%. Viewership in southern and eastern Europe was down 1% year over year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908006109/en/
"European viewers continue to embrace streaming at a rapid rate, mirroring what is happening in every corner of the world and even outpacing some regions,” said Keith Zubchevich, CEO, Conviva. “As more and more people flock to streaming, the onus is on publishers in Europe and across the globe to provide a high-quality viewing experience for consumers, but they cannot do so without consistent, accurate, real-time measurement which is also critical to grow and monetize their streaming business in a highly competitive environment."
Connected TV Devices Continue to Dominate
Connected TV devices dominated Europe as the streaming device of choice maintaining a 32% share of all viewing time. Desktop and tablets saw no change from Q2 2020, still at 14% and 11% share, respectively. Mobile phones gained 1% and smart TVs gained 2%, while gaming consoles dropped in share of viewing time, down 3%. Among big screen viewing in Europe, Samsung TV led with 19% market share followed by Chromecast at 12% and Amazon Fire TV at 11%. This is in contrast to global numbers where Roku held a solid leadership position with 31%.
Europe’s Football Leagues Celebrate Resurgence on Social Media
Q2 2021 was the first quarter since the beginning of 2020 where European sports leagues showed an increase year over year in social posts, videos and engagements. Even as the UEFA Euro 2020 tournament took precedence over league play, European leagues, including Bundesliga, La Liga, Premier League and Serie A showed strong quarter-over-quarter growth, up 68% in social engagements despite only increasing videos by 2% and posts by 20%.
Streaming Quality Improves
The report also found several facets of streaming quality in Europe improved in Q2 2021, with video start failures down 12% for the continent year over year, led by eastern Europe with a 21% improvement in video start failures. Picture quality also improved, with bitrate up 43% in Europe overall led by southern Europe with a 51% increase. Quality of streaming ads improved significantly in Q2 2021, with only 16% of ads around the world representing missed opportunities (ads that went unfilled or failed to play as expected), down from 37% the previous quarter. While global ad attempts dropped 8% from Q1 to Q2 2021, more attempts were successful, resulting in a 4% increase overall in ad impressions. What’s more, in Q2 2021, viewers spent 31% less time waiting for ads to play and ad duration decreased 3% to 27 seconds.
The full report can be downloaded here .
Methodology
Data for Conviva’s State of Streaming report was primarily collected from Conviva’s proprietary sensor technology currently embedded in 3.3 billion streaming video applications, measuring in excess of 500 million unique viewers watching 180 billion streams per year with nearly 2 trillion real-time transactions per day across more than 180 countries. Year-over-year comparisons were normalized at the customer level for accurate representations of industry growth. The social media data consists of data from over 2000 accounts, over 5 million posts, 12.5 billion video views and over 35 billion engagements across Facebook, Instagram, Twitter and YouTube.
About Conviva
Conviva is the intelligence cloud for streaming media. Powered by our patented Stream Sensor™ and Stream ID™, our real-time platform enables marketers, advertisers, tech ops, engineering and customer care teams to build, engage and monetize their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 2 trillion streaming data events daily, supporting more than 500 million unique viewers watching 180 billion streams per year across 3.3 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908006109/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom